Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.

Division of Thoracic Surgery, Memorial Sloan-Kettering Cancer Center, NY 10065, USA.
Cancer Immunology and Immunotherapy (Impact Factor: 3.64). 09/2011; 60(11):1509-27. DOI: 10.1007/s00262-011-1103-6
Source: PubMed

ABSTRACT Malignant pleural mesothelioma (MPM) is an aggressive, primary pleural malignancy with poor prognosis, hypothesized to originate from a chronic inflammatory state within the pleura. Similar to what has been observed in other solid tumors (melanoma, ovarian and colorectal cancer), clinical and pre-clinical MPM investigations have correlated anti-tumor immune responses with improved survival. As such, a better understanding of the complex MPM tumor microenvironment is imperative in strategizing successful immunotherapies. Herein, we review the immune responses vital to the development and progression of MPM, as well as assess the role of immunomodulatory therapies, highlighting recent pre-clinical and clinical immunotherapy investigations.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Malignant pleural mesothelioma (MPM) is a rare malignancy of the pleura that is frequently resistant to conventional therapies. Immunotherapy is a promising investigational approach for MPM that has shown some evidence of clinical benefit in select patients. However, tumor-induced immunosuppression is likely a major impediment to achieving optimal clinical responses to immunotherapeutic intervention. MPM contains a variable degree of infiltrating T-regulatory cells and M2 macrophages, which are believed to facilitate tumor evasion from the host immune system. Additional immunosuppressive factors identified in other human tumor types, such as tumor-associated programmed death ligand-1 expression, also may be relevant for investigation in MPM. Conventional cytoreductive therapies such as radiation, chemotherapy, and surgery may play a critical role in successful immunotherapeutic strategies by ablating intratumoral and/or systemic immunosuppressive factors, thus creating a host environment more amenable to immunotherapy. This article reviews the particular immunotherapeutic approaches currently being evaluated in MPM patients, and how immunotherapy might be rationally combined with conventional tumor cytoreductive therapies for this disease.
    American Journal of Respiratory Cell and Molecular Biology 01/2014; · 4.15 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumor-associated macrophages (TAMs) can be abundantly present in numerous cancer types. Under influence of various stimuli in the tumor microenvironment TAMs develop into a tumor-inhibitory (M1) or tumor-promoting (M2) phenotype. Recently, the role of TAMs in tumor biology and their prognostic value in cancer has become a major topic of interest. In this review we will discuss the importance of TAMs in the pathogenesis and clinical outcome of lung cancer and mesothelioma patients. In addition, the potential of TAMs as therapeutic targets will be discussed.
    Lung cancer (Amsterdam, Netherlands) 06/2013; 80(3):256–262. · 3.14 Impact Factor
  • Cancer 07/2014; · 4.90 Impact Factor


Available from